Eyal Shamir

CEO, Icecure Medical

Search every verified Eyal Shamir interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Eyal Shamir, CEO of Icecure Medical, participated in a health-tech executive panel on March 1, 2024, discussing business continuity during wartime. He stated that the October 7 attacks and subsequent war affected his company, noting that the stock experienced volatility but attributed fluctuations more to company-specific events than the conflict. Shamir said that Icecure submitted a request for FDA approval based on interim results, which he linked to receiving a Breakthrough Device Designation from the FDA. He also mentioned that the company published two European studies on breast cancer treatment, which he said helped recover the stock price. Shamir described efforts to maintain routine operations despite workforce shortages, stating that the company aims to keep activities running as normally as possible within the constraints of available personnel. He did not report that the war had a direct impact on Icecure's relationship with the FDA.